OBJECTIVES: To assess the effects of the first three rounds of a pilot colorectal screening programme based on guaiac faecal occult blood testing (gFOBT) and their implications for a national population-based programme. METHODS: A demonstration pilot programme was conducted in three Scottish NHS Boards. Residents aged between 50 and 69 years registered on the Community Health Index were included in the study. RESULTS: In the first round, the uptake was 55.0%, the positivity rate was 2.07% and the cancer detection rate was 2.1/1000 screened. In the second round, these were 53.0%, 1.90% and 1.2/1000, respectively, and in the third round, 55.3%, 1.16% and 0.7/1000, respectively. In the first round, the positive predictive value of the gFOBT was 12.0% for cancer and 36.5% for adenoma; these fell to 7.0% and 30.3% in the second round and were maintained at 7.5% and 29.1% in the third round. The percentage of screen-detected cancers diagnosed at Dukes' stage A was 49.2% in the first round, 40.1% in the second round and 36.3% in the third round. CONCLUSIONS: These results are compatible with those of previous randomised trials done in research settings, demonstrating that population-based colorectal cancer screening is feasible in Scotland and should lead to a comparable reduction in disease-specific mortality.
OBJECTIVES: To assess the effects of the first three rounds of a pilot colorectal screening programme based on guaiac faecal occult blood testing (gFOBT) and their implications for a national population-based programme. METHODS: A demonstration pilot programme was conducted in three Scottish NHS Boards. Residents aged between 50 and 69 years registered on the Community Health Index were included in the study. RESULTS: In the first round, the uptake was 55.0%, the positivity rate was 2.07% and the cancer detection rate was 2.1/1000 screened. In the second round, these were 53.0%, 1.90% and 1.2/1000, respectively, and in the third round, 55.3%, 1.16% and 0.7/1000, respectively. In the first round, the positive predictive value of the gFOBT was 12.0% for cancer and 36.5% for adenoma; these fell to 7.0% and 30.3% in the second round and were maintained at 7.5% and 29.1% in the third round. The percentage of screen-detected cancers diagnosed at Dukes' stage A was 49.2% in the first round, 40.1% in the second round and 36.3% in the third round. CONCLUSIONS: These results are compatible with those of previous randomised trials done in research settings, demonstrating that population-based colorectal cancer screening is feasible in Scotland and should lead to a comparable reduction in disease-specific mortality.
Authors: Germaine Wong; Kirsten Howard; Jeremy R Chapman; Allison Tong; Michael J Bourke; Andrew Hayen; Petra Macaskill; Richard L Hope; Narelle Williams; Anh Kieu; Richard Allen; Steven Chadban; Carol Pollock; Angela Webster; Simon D Roger; Jonathan C Craig Journal: BMC Public Health Date: 2011-06-29 Impact factor: 3.295
Authors: Monika Ferlitsch; Georg Heinze; Petra Salzl; Martha Britto-Arias; Elisabeth Waldmann; Karoline Reinhart; Christina Bannert; Elisabeth Fasching; Peter Knoflach; Werner Weiss; Michael Trauner; Arnulf Ferlitsch Journal: Med Oncol Date: 2014-08-14 Impact factor: 3.064
Authors: Robert Jc Steele; Greig Stanners; Jaroslaw Lang; David H Brewster; Francis A Carey; Callum G Fraser Journal: United European Gastroenterol J Date: 2016-01-06 Impact factor: 4.623
Authors: R J C Steele; I Kostourou; P McClements; C Watling; G Libby; D Weller; D H Brewster; R Black; F A Carey; C Fraser Journal: BMJ Date: 2010-10-27
Authors: Miroslav Zavoral; Stepan Suchanek; Ondrej Majek; Premysl Fric; Petra Minarikova; Marek Minarik; Bohumil Seifert; Ladislav Dusek Journal: World J Gastroenterol Date: 2014-04-14 Impact factor: 5.742
Authors: Christopher D Jensen; Douglas A Corley; Virginia P Quinn; Chyke A Doubeni; Ann G Zauber; Jeffrey K Lee; Wei K Zhao; Amy R Marks; Joanne E Schottinger; Nirupa R Ghai; Alexander T Lee; Richard Contreras; Carrie N Klabunde; Charles P Quesenberry; Theodore R Levin; Pauline A Mysliwiec Journal: Ann Intern Med Date: 2016-01-26 Impact factor: 25.391
Authors: Ajith K Siriwardena; James M Mason; Saifee Mullamitha; Helen C Hancock; Santhalingam Jegatheeswaran Journal: Nat Rev Clin Oncol Date: 2014-06-03 Impact factor: 66.675
Authors: M H Liedenbaum; A F van Rijn; A H de Vries; H M Dekker; M Thomeer; C J van Marrewijk; L Hol; M G W Dijkgraaf; P Fockens; P M M Bossuyt; E Dekker; J Stoker Journal: Gut Date: 2009-07-21 Impact factor: 23.059